| Nazwa produktu: |
erythromycin stearate |
| Angielska nazwa |
erythromycin stearate; Erythromycin stearate [BAN:JAN]; Abboticine; Bristamycin; CCRIS 1504; Dowmycin E; Eratrex; Erythrocin stearate; Erythromycin stearate (salt); Erythromycin steraric acid salt; Ethril; Ethril 250; Ethril 500; HSDB 4178; Meberyt; NCI-C55674; OE 7; Octadecanoic acid, compd. with erythromycin (1:1); Pfizer-E; Qidmycin; Stearic acid, compd. with erythromycin (1:1); UNII-LXW024X05M; Wyamycin S; Erythromycin octadecanoate (salt); Erythromycin, stearate (salt); octadecanoic acid - (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (1:1) (non-preferred name); (2S,3R,4S,6R)-4-(dimethylamino)-2-{[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecan-6-yl]oxy}-6-methyltetrahydro-2H-pyran-3-yl octadecanoate (non-preferred name) |
| MF |
C55H101NO14 |
| Masie cząsteczkowej |
1000.3887 |
| InChI |
InChI=1/C55H101NO14/c1-15-17-18-19-20-21-22-23-24-25-26-27-28-29-30-31-43(57)68-47-41(56(12)13)32-36(4)65-52(47)70-50-38(6)46(69-44-34-54(10,64-14)49(60)40(8)66-44)39(7)51(61)67-42(16-2)55(11,63)48(59)37(5)45(58)35(3)33-53(50,9)62/h35-42,44,46-50,52,59-60,62-63H,15-34H2,1-14H3/t35-,36-,37+,38+,39-,40+,41+,42-,44+,46+,47-,48-,49+,50-,52+,53-,54-,55-/m1/s1 |
| Nr CAS |
643-22-1 |
| EINECS |
211-396-1 |
| Struktury molekularnej |
|
| Gęstość |
1.112g/cm3 |
| Temperatura wrzenia |
941.336°C at 760 mmHg |
| Współczynnik załamania |
1.518 |
| Temperatura zapłonu |
523.101°C |
| Ciśnienie pary |
0mmHg at 25°C |
| Symbole zagrożenia |
 Xn:Harmful;
|
| Kody ryzyka |
R42/43:;
|
| Bezpieczeństwo opis |
S36:;
|
|
